Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

718

Tables (1-4)

161

Sum=921

Publishing Process of This Article

Item

Count

Browse

Download

125

Sum=201

Sep 16, 2023 (publication date) through May 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Sep 16, 2023; 11(26): 6083-6090
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6083

Table 1 Comparison of the clinical outcomes between the two study groups

CR: Complete remission; PR: Partial remission; SD: Stability; PD: Progression; ORR: Objective response rate.

Citation: Zheng L, Gan LH, Yao L, Li B, Huang YQ, Zhang FB, Kuang MQ, Fang N. Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer. World J Clin Cases 2023; 11(26): 6083-6090
URL: https://www.wjgnet.com/2307-8960/full/v11/i26/6083.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i26.6083